# Plasma proteomic evidence for increased Alzheimer's disease-related brain pathology after SARS-CoV-2 infection

1	
2	
3	
4	
5	Eugene P Duff <sup>*1,2</sup> , Henrik Zetterberg <sup>3,4,5,6,7,8</sup> , Amanda Heslegrave <sup>5</sup> , Abbas
6	Dehghan <sup>9,1,10</sup> , Paul Elliot <sup>9,1,10,11,12,13</sup> , Naomi Allen <sup>14,15</sup> , Heiko Runz <sup>16</sup> , Rhiannon Laban <sup>6</sup> , Elena
7	Veleva <sup>6</sup> , Christopher D Whelan <sup>17</sup> , Benjamin B Sun <sup>16</sup> , Paul M Matthews <sup>§1, 2,18</sup>
8	
9	<sup>1</sup> UK Dementia Research Institute Centre at Imperial College London, London,
10	UK, <sup>2</sup> Department of Brain Sciences, Faculty of Medicine, Imperial College London, London,
11	UK, <sup>3</sup> Department of Psychiatry and Neurochemistry, Institute of Neuroscience and
12	Physiology, the Sahlgrenska Academy, University of Gothenburg, Mölndal,
13	Sweden, <sup>4</sup> Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal,
14	Sweden, <sup>5</sup> Department of Neurodegenerative Disease, UCL Institute of Neurology, University
15	College London, London, UK, <sup>6</sup> UK Dementia Research Institute Centre at UCL, London,
16	UK, <sup>7</sup> Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China, <sup>8</sup> Wisconsin
17	Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and
18	Public Health, Madison, WI, USA, <sup>9</sup> Department of Epidemiology and Biostatistics, Faculty of
19	Medicine, Imperial College London, London, UK, <sup>10</sup> MRC Centre for Environment and Health,
20	Imperial College London, London, UK, <sup>11</sup> British Heart Foundation Centre of Research
21	Excellence, Imperial College London, London, <sup>12</sup> National Institute for Health Research
22	Biomedical Research Centre, Imperial College London, London, <sup>13</sup> Health Data Research UK
23	at Imperial College London, Imperial College London, London, <sup>14</sup> Nuffield Department of
24	Population Health, University of Oxford, Oxford, UK, ' <sup>3</sup> UK Biobank, Stockport,
25	UK, "Translational Sciences, Biogen, Cambridge, MA, USA, "Neuroscience Data Science,
26	Janssen Research & Development, Cambridge, MA, USA, '° The Rosalind Franklin Institute,
27	Harwell Science and Innovation Campus, Didcot, UK
28	
29	*Communicating author: Eugene Duff <u>e.duff@imperial.ac.uk</u>
30	<sup>3</sup> Senior author: Paul Matthews <u>p.matthews@imperial.ac.uk</u>
31	
32	Kau Manda, COVID 40, places anota anica, his markan, hata amudaid/(4,40). Al-hairs air
33	key vvoras: UUVID-19, plasma proteomics, biomarkers, beta-amyloid(1-42), Alzheimer's
34	aisease, aementia

# 36 Abstract

37 Prior studies have suggested that systemic viral infections may increase risks of dementia. 38 Whether this holds true for SARS-CoV-2 virus infections remains uncertain but is of great 39 consequence for predicting future dementia rates. We examined this by comparing changes 40 in plasma biomarkers in UK Biobank participants before and after serology confirmed SARS-41 CoV-2 infections. We discovered biomarker changes associated with increased AD risk 42 within this population. SARS-CoV-2 infection was associated with reduced plasma 43 Aβ42:Aβ40 concentration ratios, and in more vulnerable participants, lower plasma Aβ42 44 and higher plasma pTau-181. These biomarker changes, which have been associated with 45 brain beta-amyloid accumulation in prodromal AD, were associated here with increased 46 brain imaging signatures of AD, poorer cognitive scores, and worse assessments of overall 47 health. Changes were greater in participants who had been hospitalised with COVID-19 or 48 had previously reported hypertension. Our data provide evidence for the hypothesis that 49 SARS-CoV-2 can be associated with accelerating brain pathology related to prodromal AD. 50

# 52 Introduction

53

54 Exposures to infectious diseases in early life and adulthood have been linked to increased 55 risk for neurodegenerative and other systemic disease <sup>1–4</sup>. Viral encephalitis or meningitis, influenza, pneumonia and viral intestinal infections all may increase risks of Alzheimer's 56 57 disease (AD)<sup>1</sup>, Vaccinations to prevent these diseases may also have protective effects<sup>5</sup>. 58 A variety of central and peripheral mechanisms could underly these effects, including tissue injury during the acute phase of infections or chronic secondary inflammatory processes<sup>6-8</sup>. 59 60 However, uncertainty remains. The epidemiological observations are confounded by 61 heterogeneity of infections, and mechanistic hypotheses have been limited by the lack of 62 large scale, harmonised, prospective observations in human populations that allow common 63 factors that predispose both to infection and to dementia to be discriminated from any 64 potential causal relationships of infection to dementia.

65

66 The recent COVID-19 pandemic provided a common viral exposure to large populations 67 over well-defined periods. SARS-CoV-2 initiates a systemic inflammatory response, which persists in many patients beyond the acute phase and increases susceptibility to several 68 systemic diseases. Although the virus is not neurotrophic 9-11, impairment of cognition, and 69 brain structural changes have been reported as sequelae of SARS-CoV-2 infections, even 70 amongst people who did not require hospitalisation or experience long-COVID<sup>10,12</sup>. Initial 71 72 evidence for raised dementia rates in vulnerable populations following serious COVID have been reported<sup>13</sup>. Preclinical studies have identified potential mechanisms for increased brain 73 inflammatory pathology with SARS-CoV-2 that could account for these observations<sup>7,14,15</sup>. 74 75 These reports suggested to us that the COVID pandemic could provide a "natural 76 experiment" for testing whether infection-associated systemic infection can initiate or 77 potentiate brain pathology associated with AD. The urgency of the question seemed clear: 78 the global scale of the pandemic and aging populations make a better understanding of the 79 potential impact of COVID-19 and other infections on the prevalence of future dementias a public health priority<sup>10,16</sup>. 80

81

82 Recently developed high-throughput plasma proteomic biomarkers that provide biologically-83 based markers of risk or the onset of dementia years in advance of the expression of 84 symptoms or of a clinical diagnosis can provide sensitive outcome measures for a study of early dementia pathology<sup>17-24</sup>. Amongst the best characterised plasma proteomic markers 85 for AD are lowered beta amyloid-(1-42) (A $\beta_{42}$ ), its ratio with beta amyloid-1-40 (A $\beta_{42}$ :A $\beta_{40}$ ) 86 87 and raised phosphorylated tau (pTau), all of which accompany the accumulation of pathological proteins in the brain and clinical progression of AD <sup>17,25-27</sup> Concentrations of 88 neurofilament light (NFL) (a non-specific marker of neuronal injury) and glial fibrillary acidic 89 90 protein (GFAP) (which is associated with astrocyte activation) also are found to increase in plasma in early AD <sup>28–30</sup>. Studies have identified changes in these plasma proteins prior to 91 dementia diagnoses and brain amyloid positivity by PET<sup>17,23,25,30</sup>. Decreases in plasma 92  $A\beta_{42}$ :  $A\beta_{40}$  may precede the diagnosis of AD by up to 20 years, total Tau by 15 years, with 93 increases in NfL and GFAP detected closer to diagnosis<sup>24</sup>. These biomarkers provide the 94 95 opportunity to assess the effect of mild to moderate SARS-CoV-2 in healthy populations on 96 Alzheimer's prodromal pathology and risk. 97

#### 98

99 Raised levels of these dementia-related proteins have been reported in patients in the context of acute COVID-19<sup>19,31,32</sup>. However, interpretation of these studies is confounded by 100 the potential for "reverse causation", as many risk factors for severe COVID-19 are also risk 101 102 factors for dementia. Complications of severe infections also can independently increase 103 biomarker levels. To robustly test for relationships between SARS-CoV-2 infection and brain 104 pathology for AD, longitudinal study designs that define changes from before to after 105 infection are needed. Symptomatically mild-to-moderate infections are an ideal study target 106 as they are less confounded by other factors associated with severe illness and prolonged 107 intensive care. Furthermore, given that dementias also are associated with genetic 108 background, aging, and health status, analyses need to be able to take these factors into 109 account for elucidation of the independent effects of infection. 110 111 We were able to apply a design incorporating these principles to address the question of 112 whether SARS-CoV-2 infection initiates or potentiates brain pathology associated with 113 prodromal AD. We took advantage of the longitudinal blood sampling and clinical data

114 acquisition in UK Biobank in combination with that study's surveillance for SARS-CoV-2 115 exposure serology during the early stage of the UK COVID-19 pandemic (2020-21). Here 116 we report results from over 1200 UK Biobank participants tested longitudinally for a range of 117 plasma proteomic biomarkers. Our primary outcome measures were plasma levels of  $A\beta_{42}$ 118  $A\beta_{40}$ , the  $A\beta_{42}$ :  $A\beta_{40}$  ratio, pTau-181, NfL and GFAP (Quanterix Simoa assays). We were 119 able to test for changes in these biomarkers with infection and compare these changes to 120 those found in a demographically matched group who were sampled prospectively over the 121 same interval but who were not infected with SARS-CoV-2. This longitudinal, prospective, 122 matched case-control design permitted the modelling of changes in AD biomarkers with 123 control for a variety of potential confounders including aging and baseline differences in 124 genetic backgrounds, sex and health status between cases and controls. The extensive 125 genetic, imaging and health data of the UK Biobank dataset allowed detailed assessment of 126 confounds and relationships. In a subset of participants, we also were able to assess 127 plasma levels of a selection of over 1400 proteins obtained from a high-throughput Olink 128 Explore general proteomic platform, which provided the opportunity to assess the impact of SARS-CoV-2 infection on inflammatory proteins and proteins associated with risks of other 129 chronic diseases <sup>20,33,34</sup>. 130

# 131 **Results**

#### 132 Study Population

133 We studied plasma proteomic biomarkers of AD and dementia risk, as well as proteins from 134 a general proteomic panel, brain images and other health data that were made available 135 from 1252 UK Biobank participants who had been recruited for the UK Biobank COVID-19 study (626 matched case-control pairs, 331 female)<sup>10</sup>. All participants had taken part in an 136 137 imaging assessment session before the pandemic onset (baseline, May 2014 - March 2020). 138 Participants were 46-80 years of age at this session (Fig. 1b). Individuals from these 139 assessments who were determined to have previously had SARS-CoV-2 infection by at least 140 one of: home-based lateral flow SARS-CoV-2 antibody test, PCR antigen (swab) test, GP

141 records or public health records were invited for the COVID-19 imaging study (see Methods). 142 Symptoms related to COVID-19 in cases were mostly mild, but 20 participants were 143 hospitalised for COVID-19 or its complications. Of 289 cases for whom vaccination status 144 could be determined, 40 had data indicating they had been vaccinated before their first 145 positive COVID test. Cases were matched individually to eligible controls (defined based on 146 age [+/- 6 months], sex, ethnicity [white/non-white], and location and date of initial imaging 147 assessment [+/- 6 months]) who had no record of confirmed or suspected SARS-CoV-2 148 infection at the time of the repeat assessment. The COVID imaging assessments occurred 149 during the UK COVID-19 pandemic (February 2021 - February 2022). Intervals between the 150 two assessment sessions ranged from 12-82 months, matched for case-control pairs (Fig. 1 151 d.e.f). Blood samples for plasma proteomics were obtained at both imaging assessment 152 sessions.

153

154 We characterised cases and controls for potential comorbidities and other factors (Table 1). 155 Some characteristics differed between case and control groups, reflecting lifestyle factors 156 that could increase the likelihood of early infection: more were employed prior to the 157 pandemic (395 vs 364); more cases (n=18) than controls (n=6) identified as "key workers" 158 during the pandemic (p=0.023); household sizes were larger on average (p=0.007\*) and cases were more active on average (p=0.002\*). Cases were slightly heavier (1.4kg) than 159 160 controls (p=0.028) (although hip/waist ratio and obesity rates did not differ). Other AD 161 comorbidities did not show statistically significant differences across cases and controls. 162 Cases had slightly higher numbers in some factors including smoking and reported prior 163 hypertension. 164

165 Single molecule array (Simoa) ultrasensitive measures of plasma amyloid- $\beta_{42}$  (A $\beta$ 42),

amyloid- $\beta_{40}$  (A $\beta$ 42), pTau-181, glial fibrillary acidic protein (GFAP) and neurofilament light

167 (NfL) were available on plasma collected before and after onset of the COVID pandemic for

168 cases and for controls (see Online Methods). A complete set of longitudinal data was

available for 600 cases and for 600 matched controls; the remaining cases and controls
 were missing data from one or more assay. Olink antibody-based proximity extension assa

were missing data from one or more assay. Olink antibody-based proximity extension assay proteomic measurements of concentrations of 1452 proteins (including additional assays for

172 NFL and GFAP) in the same plasma samples were available for 277 of the case-control

173 pairs<sup>35</sup>.

174





Fig. 1. a. Experimental design. Protein concentrations were assayed from plasma samples acquired from the UK
Biobank imaging assessment visits, the second of which was specifically recruited for the study of COVID-19. b.
Distribution of participant ages at the pandemic assessment. c. Sources of evidence for case selection. Antibody
- home-based lateral flow SARS-CoV-2 antibody test; Antigen – PCR antigen (swab) test; Health records: GP
and/or hospital records d. Distribution of pre-pandemic assessment visit dates e. Distribution of pandemic
assessment visit dates f. Distribution of intervals between assessments. g. Estimated dates of COVID symptoms (from participants with antigen test results).

185



186

Fig. 2. Schematic of data availability for the study. Primary analyses focus on 624 individually matched cases
 and controls from the COVID19 imaging repeat study with SIMOA plasma proteomic data. Full details of
 participant selection and control matching for the COVID study can be found at

- biobank.ndph.ox.ac.uk/ukb/ukb/docs/casecontrol\_covidimaging.pdf.
- 191
- 192
- 193
- 194
- 195

#### 196 197

		CASES	MATCHED CONTROLS	P-VALUE	Ν
DEMOGRAPHICS Age (baseline)		60.21 (7.41)	60.23 (7.41)	0.324	624
	Age (pandemic)	63.45 (7.02)	63.46 (7.02)	0.456	624
	Sex	0.47 (0.50)	0.47 (0.50)	1.000	624
	Height	170.34 (8.82)	169.89 (9.08)	0.222	622
	Weight	77.06 (15.02)	75.63 (14.54)	0.028	593
	Ethnicity (white)	0.93 (0.26)	0.92 (0.28)	0.437	624
GENETICS	APOE-ε3e4	123	110	0.869	423
	APOE-ε4e4	11	9	0.788	423
	APOE-ε3e2	73	62	0.547	423
HEALTH MEASURE	Hip/Waist Ratio	1.16 (0.12)	1.16 (0.12)	0.831	595
	BMI	26.56 (4.21)	26.23 (4.17)	0.110	593
	BP (sys)	137.23 (19.22)	137.26 (18.58)	0.984	424
	BP (dia)	79.26 (11.04)	79.33 (10.80)	0.625	424
	Hand Grip	32.01 (10.26)	31.75 (10.42)	0.691	587
	Chest wheeze	90	94	0.872	607
	Health self-rating	3.02 (0.62)	3.09 (0.64)	0.075	618
	GFR (pre)	88.12 (10.52)	86.62 (10.87)	0.071	225
LIFE STATUS	Alcohol Intake Freq	3.19 (1.34)	3.18 (1.32)	0.966	618
	Smoker	26	18	0.283	619
	Deprivation	16.50 (11.79)	15.56 (12.14)	0.230	590
	inco me	2.83 (1.70)	2.82 (1.75)	0.893	620
	Number in Household	2.46 (1.19)	2.30 (1.09)	0.007	620
	Key Worker	18	6	0.023	624
	Employed	395	364	0.061	614
	Social Isolation	34	48	0.137	624
	Moderate activity (min/d)	63.25 (79.19)	52.29 (55.34)	0.002	503
	Vigorous activity (min/d)	42.92 (41.70)	42.36 (39.26)	0.576	293
COMORBIDITY	Type II Diabetes	17	15	0.858	624
	Heart Condition	108	100	0.595	624
	Obesity	113	107	0.710	624
	Hypertension	145	127	0.244	624
	Depression	26	20	0.453	624
	IBS	39	34	0.629	624
	COPD	4	3	1.000	624
	Emphysema	3	4	1.000	624
MEDICATIONS	Blood pressure medication	53	46	0.530	624
	Cholesterol medication	46	44	0.913	624
	Diabetes medications	3	3	1.000	624
	COVID vaccinated	384	388	0.351	286
COGNITION	Cognitive Ability Score	32.84 (7.27)	32.94 (7.59)	0.967	407
NEUROIMAGING	AD Neuroimaging Phenotype	-2.29 (0.66)	-2.30 (0.66)	0.799	590

198

199 200

Table 1. Comparisons of baseline characteristics of cases and controls. P-values reflect paired t-tests across matched case and control pairs (uncorrected). BMI: Body Mass Index, BP: blood pressure, BP medication:

Prescribed anti-hypertensive medications. UK Biobank fields and derivation of measures can be found in
 Supplementary table 1 and Online Methods.

203

# <sup>204</sup> The plasma Aβ42:Aβ40 ratio is reduced after SARS-CoV-2

#### 205 infection

To test for effects of SARS-CoV-2 infection on preclinical AD brain pathology, Twhether
 infection status affected longitudinal changes in concentrations of plasma Aβ40, Aβ42,
 pTau-181, NFL and GFAP, with the baseline assessment completed before the COVID-19
 pandemic and the repeat assessment made during the pandemic, after cases had
 developed serological evidence for SARS-CoV-2 infection<sup>17,36</sup>. In addition to the plasma
 concentrations, we also assessed the Aβ42:Aβ40 concentration ratio<sup>26,27</sup>.

212

213 We fit linear models describing each participant's pandemic-session biomarker levels in 214 terms of their baseline, pre-pandemic levels, time interval between the two sample 215 acquisitions, age, sex, and their individual case (serology positive, post SARS-CoV-2 216 infection) or control (serology negative, no evidence of prior SARS-CoV-2 infection) status 217 (see Error! Reference source not found.). These models therefore modelled changes in 218 the plasma biomarker levels between assessments, with the case-control regressor 219 identifying differences in these changes associated specifically with SARS-CoV-2 infection. 220 We fit further models assessing the associations of a variety of comorbidities and other 221 factors with biomarker levels at baseline and longitudinally (Online Methods, Supplementary 222 table 1).

223

224 Average participant plasma concentrations of Aβ42, the Aβ42:Aβ40 ratio, and pTau-181 225 decreased between pre-pandemic and pandemic assessments for all participants (cases 226 and controls), while concentrations of A $\beta$ 40, NfL and GFAP increased (all p<0.0001, paired 227 t-tests). Statistical testing of the case-control model parameters found SARS-CoV-2 228 infection was associated with a significantly greater reduction in the AB42:AB40 ratio (2%) 229 drop from baseline, False Discovery Rate [FDR] significant \*\*p-value, p=0.001) (Fig. 3, 230 Supplementary table 2). These results were maintained when an extended model including 231 potential confounders was used (Supplementary table 3). The estimated effect of SARS-232 CoV-2 on the A $\beta$ 42:A $\beta$ 40 ratio was comparable to the effect of 4 years of aging (-0.5%) 233 change in Aβ42:Aβ40 ratio per year of age, estimated at baseline), and around half the 234 average effect of heterozygosity for APOE-ɛ4 (APOE-ɛ4 heterozygous participants showed a 235 3.9% lower AB42:AB40 ratio relative to APOE-£3 homozygous in the baseline assessment 236 sessions). Other comparable comorbidities of AD did not show a statistically significant 237 238 AB42:AB40 ratio amongst cases were associated with greater severity of symptomatic 239 infections: cases who were hospitalised with COVID-19 showed over twice the magnitude of 240 reduction relative to non-hospitalised cases (5.3% vs 2.1%). 241

- 242
- 243



244

Fig. 3. Standardised model parameters for Case/Control term in each of the AD-protein change models.
Parameters represent the SARS-CoV-2 infection associated effect on change in protein levels between prepandemic and pandemic assessment sessions. Aβ42:Aβ40 ratios showed significant relative reductions in
SARS-CoV-2 individuals. P-values correspond to one-sided tests in the directory of previously reported
biomarker associations with AD. Full model fits are in Supplementary tables 2 and 3 (basic and extended
models).

251

# Greater changes in both plasma Aβ42 and pTau-181 after SARS-CoV-2 infections were found in older participants

254

255 Participants who were older or had prior lifestyle or health conditions that are risk factors for 256 neurodegenerative disease are likely to be more vulnerable to infection-related 257 neurodegenerative pathology. Age is a key risk factor both for AD and for the severity of 258 COVID-19 but the relationships between age and risk are non-linear as older people become 259 more vulnerable to severe disease symptoms in later years<sup>37</sup>. To test for specific effects of 260 SARS-CoV-2 on plasma protein level changes in older, more vulnerable study participants, 261 we used regressors reflecting an age-related vulnerability score derived from observed associations between age and severe neurological outcomes for COVID-19 (Fig. 4c)<sup>37</sup>. This 262 score has previously been used to analyse SARS-CoV-2 changes in MRI measures<sup>10</sup>. We 263 264 assessed models that included this score and its interaction with case-control status to 265 assess whether age-related-vulnerability predicted changes in AD-proteins between 266 assessments with or without dependence on SARS-CoV-2 infection status (Online Methods). 267 268 Across both cases and controls, a higher age-related-vulnerability score was associated with 269 greater decreases in Aβ42:Aβ40 ratio and greater increases in pTau, NfL and GFAP 270 concentrations between the pre-pandemic and pandemic assessment sessions (Fig. 4a, 271 Supplementary table 4). Assessing the interaction of age-related-vulnerability score and 272 case-control status found age-related-vulnerability score dependent increases in pTau-181 273 (p=0.016\*\*) and decreases in AB42 (p=0.029\*) in those exposed to SARS-CoV-2 relative to 274 controls (Fig. 4b, Supplementary table 4). These effects were strengthened when an 275 extended set of confounds were modelled (Supplementary table 5). Age-resolved plots 276 indicate that SARS-CoV-2 cases begin to show greater changes in AD proteins from around 277 70 years of age (Fig. 5). For an average 75-year-old participant, this model estimates an

278 additional 4% increase in pTau-181, a 3% decrease in Aβ40 in SARS-CoV-2 positive

279 participants, alongside a 5.5% change in Aβ42:Aβ40 ratio (Online Methods).

#### 280



281 282

202

Fig. 4. Standardised model parameters for models including age-dependent vulnerability terms in each of the
 AD-protein change models. a. parameters for age-dependent vulnerability term. b. parameters for age-dependent
 vulnerability term interaction with case-control status. c. Age-dependent vulnerability term weightings P-values
 correspond to one-sided tests corresponding to previously reported associations with AD. Full model fits are in
 Supplementary tables 4 and 5 (basic and extended models).



288 289 290

#### AD risk factors associated with accelerated changes in plasma protein biomarker levels in cases and controls.

293 We assessed similar models to examine the influence of a variety of further comorbidities for 294 AD and other factors on the protein biomarkers (Supplementary table 1). Within assessment 295 sessions, AD proteins showed rich set of associations with comorbidities and other factors 296 (Fig. 6a, Supplementary table 6). A lower Aβ42:Aβ40 ratio was associated individuals with 297 an APOE-ɛ4 variant (p=0.001\*\*) and current smokers (p=0.015\*). While age was matched 298 across cases and controls, rates of these variates varied slightly across cases and controls 299 (Table 1) and contributed to a difference in pre-pandemic Aβ42:Aβ40 ratios between cases 300 and controls (0.0747 vs 0.0765, p=0.0145) (Supplementary table 7). These differences were 301 attenuated by regressing APOE and Smoking status. While differences in baseline would

Fig. 5. Time plots SARS-CoV-2 for plasma protein levels a. Aβ40 b. Aβ42 c. Aβ42:Aβ40 d. pTau-181. Plots show 7-year rolling mean with 90% Cls on the mean.

not directly affect the longitudinal analysis of SARS-CoV-2 associated differences, including
 these factors in our primary models indicated that these effects were not confounding
 observed SARS-CoV-2 differences (Supplementary table 8).

305

306 Certain prior factors were associated with the extent of longitudinal changes in the AD 307 proteins (Fig. 6b, Supplementary table 9, Online Methods). Independent of case-control 308 status, male sex, higher hip/waist ratio, and poorer health self-rating were associated with 309 greater increases in pTau-181 across assessments (p<0.05\*\*). Type II Diabetes appeared 310 to be associated with reduced changes. Analysis with a model accounting for these 311 potential confounds indicated that these differences could not account for the differences in 312 protein levels associated with SARS-CoV-2 infection seen above (Supplementary table 10). 313 314 A low Glomerular Filtration Rate (GFR) indicates poor kidney function and is known to

influence plasma protein levels<sup>39</sup> and alter Alzheimer's disease biomarker protein levels 315 without increasing disease risk<sup>38</sup>. Here, lower estimated GFR (available for n=225 cases) 316 317 was associated with significantly increased plasma concentrations of protein levels at 318 baseline (Fig. 6a). Estimated GFR did not show a significant difference between cases and 319 controls (Table 1). Higher GFR was associated with greater reductions in Aβ42 and Aβ40 320 protein concentrations between assessments, but not with changes in A642:A640 ratio (Fig. 321 6b). When GFR was included as a confounding covariate in models of AD biomarker 322 change, it had negligible impact on effect sizes for SARS-CoV-2-associated differences in 323 Aβ42:Aβ40 (Supplementary table 11). 324



325 326

Fig. 6. Associations between AD protein levels and comorbidities and other factors, as determined from
regression models across all cases and controls. Shading shows the magnitudes of standardised betas, where
model parameter fits in models controlling for age, sex and time interval between assessments. a. Associations
within baseline assessment data only. Red colours represent positive associations. b. Associations of factors
with the change in AD protein levels across assessments. Red colours represent a positive association of factors

331 332 with levels of protein biomarker being higher in the post-pandemic assessment session. c. Interaction of

association from (b) with case/control status (case=+1). Red colours represent a greater positive association in

333 cases. (b). \*: p<0.05 \*\*: p<0.05 FDR corrected. Maps masked at abs(p)=0.20. BMI: body mass index, BP: blood

334 335 pressure, GFR: estimated glomerular filtration rate, IBS: irritable bowel syndrome, pTau-181: phosphorylated Tau 181, NfL: neurofilament light.

Prior hypertension, brain structural features associated with AD 336 and plasma inflammatory protein levels were associated with 337 greater SARS-CoV-2 infection-related changes in plasma AD 338 biomarkers 339

340

341 Several factors showed specific associations with changes in AD-biomarker levels between 342 assessment sessions in SARS-CoV-2 positive participants (Fig. 6c, Supplementary table 343 12). Hypertension was associated with greater reductions in amyloid markers of AD 344 pathology in cases positive for SARS-CoV-2 infection (diastolic blood pressure: reduced 345 Aβ42:Aβ40 ratio p=0.002\*\*; hypertension: reduced Aβ42:Aβ40 ratio p=0.0018\*; reduced 346 Aβ42 p=0.004\*\*). Hypertension has been linked to both more severe COVID-19 347 symptoms<sup>39</sup>, and the progression of AD fluid biomarkers<sup>40</sup>. While APOE genotype has been associated with COVID-19 severity previously 44,45 our analyses showed no clear effects of 348 prior vaccination (p=0.44) or APOE status on plasma protein changes from pre- to post-349 350 pandemic in cases compared to controls. Sex also did not have a significant effect on the 351 AD plasma proteomic changes.

352

353 A brain imaging signature was developed previously from MRI volumetric and cortical 354 thickness measures in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database <sup>41</sup>, 355 and shown to be associated with higher rates of AD and lower memory and cognitive scores among UK Biobank participants<sup>41</sup>. The AD signature values were standardised for sex, age, 356 357 and intracranial volume, and showed no case-control differences at baseline (p=0.779) or 358 significant associations with AD protein levels prior to SARS-CoV-2 infection (all p>0.1). 359 However, we found that higher values of this signature at baseline were associated with 360 greater increases in pTau-181 ( $p=0.012^{**}$ ) and greater reductions in A $\beta$ 42 ( $p=0.015^{**}$ ) after 361 SARS-CoV-2 infection relative to the matched controls (Fig. 6c, Supplementary table 13). 362

363 We also assessed whether baseline levels of a set of Olink inflammatory proteins associated 364 with COVID or AD were associated with neurodegenerative biomarker changes 365 (Supplementary table 14). None of these protein levels differed between cases and controls 366 at the pre-pandemic session (Supplementary table 15). Higher baseline levels of 367 Macrophage Inhibitory Factor (MIF) predicted greater reductions in Aß protein levels across 368 both cases and controls (Supplementary table 16). Higher baseline levels of YKL-40 (or 369 chitinase-3 like-protein-1) were associated with greater Aβ42:Aβ40 reductions specifically in 370 the SARS-CoV-2 group (standardised beta = -0.08, p= $0.006^{**}$ ) (Supplementary table 17). 371 YKL-40 is highly expressed in astrocytes during neuroinflammation and is associated with increased brain amyloid and AD symptoms<sup>42,43</sup>. 372

# Associations between changes in plasma AD biomarkers and Olink protein levels

376

377 Peripheral inflammation is a probable component of a pathway for SARS-CoV-2 induced 378 amyloid pathology. While in mild cases of COVID-19 inflammatory protein levels have been 379 reported to normalise in the time frame of the present study (median time since last SARS-CoV-2 positive test = 68 days)<sup>46</sup>, it is possible that some persistent inflammation, such as 380 381 that seen in long-COVID, plays a role in the AD-related pathology we observe. Of 13 382 proteins assessed, TRAIL protein (TNFSF10), an apoptotic TNF cytokine was significantly 383 reduced after SARS-CoV-2 infection (p=0.002\*\*) (Supplementary table 18). This protein has 384 been reported to be lower in patients with severe COVID<sup>47</sup> and lower levels have been 385 identified as a biomarker associated with AD risk in separate UK Biobank plasma samples and disease records<sup>20</sup>. Inflammation would be expected to be higher in participants with 386 387 severe symptoms. Those participants who had been hospitalised with COVID-19 showed 388 increased levels of Interleukin 6 ( $p=0.01^*$ ) and the long pentraxin PTX3 ( $p=0.012^*$ ) in the 389 pandemic assessment relative to controls.

390

Using disease reports from the health records of 47,600 of the UK biobank participants<sup>20</sup>, the 391 392 Olink proteins have previously been used to estimate weightings providing individual disease 393 risk scores (ProteinScores) (online Methods). We were able to estimate 19 of these scores 394 for the pre-pandemic and post-pandemic assessment sessions to assess whether they were 395 associated with changes in AD-biomarkers. There were no differences in disease risk 396 scores between cases and controls at baseline, and the incidence of all disease risks 397 (except endometriosis) increased with age. SARS-CoV-2 was associated with increases in 398 disease risk scores for several co-morbidities of Alzheimer's disease: type 2 diabetes 399 (p=0.008\*\*), chronic obstructive pulmonary disease (COPD) (p=0.001\*), ischaemic stroke 400 (p=0.0001\*) and heart disease (p=0.011\*) (Supplementary table 19). These changes are 401 consistent with recent epidemiological reports of increased incidence of some of these diseases after the pandemic <sup>48</sup>. The AD risk score, weighted heavily to NfL and GFAP 402 403 levels, did not show a significant increase (p=0.108).

# Associations between AD biomarker changes and changes in neuroimaging, cognitive performance, and general health

#### 406 measures

407 Previous work using the UK Biobank brain imaging data identified changes in brain structure following SARS-CoV-2 infection, linked to age-related-vulnerability<sup>10</sup>. We assessed whether 408 409 there was evidence that these changes could be associated specifically with the AD-related 410 changes we observe. An interaction analysis with the age-dependent vulnerability score 411 showed evidence (p=0.027) for increases in the Alzheimer's Disease Neuroimaging Initiative 412 (ADNI)-derived AD structural brain phenotype score after SARS-CoV-2 infection in older 413 participants. Increased AD brain signature scores were associated with increased pTau-181 414 and NfL between visits (p=0.015\* and p=0.031, respectively). 415

416 Recent work has highlighted that COVID-19 is associated with long-lasting impairments in 417 multiple cognitive domains<sup>12</sup>. To test for relationships between cognitive performance and 418 SARS-CoV-2 infection in this population, we evaluated a measure of general cognitive ability 419 derived from UK Biobank cognitive tests (see Methods)<sup>49</sup>. SARS-CoV-2 infection was 420 associated with an additional 2.05% reduction in this measure over controls, equivalent to 421 almost two years of age-related decline (1.16%/year, p=0.029). However, these changes 422 were not strongly correlated with the AD biomarkers, which can change years prior to 423 cognitive changes. Reductions in cognitive scores were associated with reductions in Aβ42 424 (p=0.037) and increases in plasma Tau-181  $(p=0.011^*)$ . 425 426 Finally, participants were also asked to rate their overall health between poor and excellent. 427 There were no significant differences at baseline between cases and controls. However,

428 cases showed greater deterioration in their overall health ratings (2.3% p=0.007\*) between

429 the assessment visits than did the controls. While prior health self-ratings affected pTau-181

- 430 (above), changes in general health self-ratings across were not associated with AD protein431 levels.
- 432 **Discussion**
- 433

434 SARS-CoV-2 infections can have a wide range of profound and long-lasting effects on 435 human health. There have been persistent raised levels of illness and mortality since the pandemic, even in people who experienced only clinically mild cases of COVID-19<sup>12,48,50,51</sup>. 436 437 However, evidence for the effect of COVID-19 on risk for late-life dementia has been lacking. 438 Here, using longitudinal ultrasensitive Simoa platform plasma AB and pTau measures that 439 are relatively specific and sensitive for AD and a demographically matched case-control 440 design, we discovered plasma proteomic biomarker evidence for prodromal AD pathology 441 after SARS-CoV-2 infection amongst UK Biobank participants. These people largely 442 experienced mild to moderate symptoms. Despite this, SARS-CoV-2 infection was 443 associated with significant reductions in Aβ42:Aβ40 between baseline and pandemic 444 assessment visits. Moreover, decreases in plasma AB42 and increases in pTau-181 were 445 seen in older participants and those with MRI brain signatures of AD. These protein biomarker changes have all previously been associated with increased AD risk<sup>17,26,36,52</sup>. 446 447 While some of these changes have been associated previously with severe COVID-19 in acute settings<sup>19,53</sup>, to our knowledge they have not been assessed in the post-acute setting 448 449 for largely mild cases. Together, our results provide evidence that SARS-CoV-2 infection 450 initiates or accelerates brain pathology associated with AD risk and suggests increased risk 451 of AD after infection.

452

453 Changes in plasma A $\beta$ 42:A $\beta$ 40 have been found to be the earliest detectable plasma 454 biomarker change in preclinical stages of AD<sup>24</sup> and are associated with brain amyloid 455 accumulation even in cognitively normal participants<sup>27</sup>. The observed mean magnitude of 456 the reduction in plasma A $\beta$ 42:A $\beta$ 40 after SARS-CoV-2 infection was substantial: equivalent 457 to 4 years of aging (based on the baseline pre-pandemic data for this participant group) and 458 60% of the effect size of inheriting a single *APOE-* $\epsilon$ 4 allele. Effect sizes were larger in the 459 subgroup from our study who were hospitalised for COVID-19, and for those reporting prior

460 hypertension, suggesting that the impact on brain pathology is likely to increase with more461 severe infection.

462

We observed decreases in plasma A $\beta$ 42 and increases in pTau-181 associated with SARS-CoV-2 in participants with higher age-dependent vulnerability scores and in those with MRI brain signatures of AD prior to infection. In prior studies, concordant changes in A $\beta$ 42 and pTau-181 follow A $\beta$ 42:A $\beta$ 40 in the progression of plasma biomarkers in pre-AD <sup>24,25</sup> and have been associated with increasing brain A $\beta$  load <sup>17,26,36,52,54</sup>. These changes in more vulnerable participants were associated with brain structural changes, increased cognitive deficits, and decrements in measures of general health quality.

470

471 Increases in NfL and GFAP in CSF and plasma have been reported previously with Alzheimer's disease, MCI, and acute COVID<sup>17,26,53,55,56</sup>. Here we did not find increased 472 levels in either following SARS-CoV-2 infection. NfL and GFAP are markers of neural injury 473 474 and astroglial activation, respectively, which are more predominant in later stages of AD 475 progression. While the plasma Aβ42:Aβ40 ratio have been found to decrease from control 476 levels up to 18 years prior to an AD diagnosis, increases in plasma NfL and decreases in hippocampal volume were not detectable until at least 9 years later<sup>24</sup>. We would expect few 477 participants to have such progressed AD pathology. The absence of changes in these 478 479 proteins also aligns with observations made during and after COVID. In hospitalised COVID 480 patients, plasma NFL and GFAP concentrations have been observed to be raised, but they 481 returned to control levels within 3 months for the majority of patients <sup>57</sup>.

482

483 There are a variety of mechanisms by which mild to moderate SARS-CoV-2 infection may 484 increase the brain beta-amyloid load. Brain beta-amyloid production and aggregation can be 485 potentiated by stress, infection and pathological conditions including diabetes, stroke and vascular disease <sup>58,59</sup>. Epidemiological studies have suggested that a wide range of 486 systemic infections may be associated with increased risks of AD <sup>60,61</sup>. SARS-CoV-2 is not 487 neurotrophic<sup>62</sup>, but infection is associated with systemic inflammatory activation<sup>63</sup>. With 488 489 associations between peripheral inflammatory events and dementia identified in numerous 490 studies<sup>64</sup>, possible neuroimmune mechanisms of AD pathogenesis are increasingly being studied <sup>65–67</sup>. Pre-clinical studies of peripheral inflammatory challenges have found evidence 491 492 both for potentiation of brain microgliosis and for impairment of microglial clearance of betaamyloid and the progression of tau pathology <sup>7,68</sup> Levels of midlife systemic inflammatory 493 494 markers have been associated directly with late-life relative brain atrophy comparable to that associated with the APOE4 allele<sup>69</sup>, an effect size mirroring that observed here. 495

496

497 Peripheral inflammation may influence CNS inflammatory processes in several ways. For 498 example, systemic infection can enhance CNS inflammation directly by trafficking of 499 activated immune cells or indirectly with increases in systemic cytokines or inflammatory 500 activation of endothelial cells and breakdown of the blood-brain-barrier to allow leak of chronically pro-inflammatory plasma proteins into the CNS<sup>14,15</sup>. Direct infection of vascular 501 endothelial cells by SARS-CoV-2 would enhance this <sup>70</sup>. Long-lasting immunological 502 503 changes in patients could maintain these effects for prolonged periods even in mild-to-504 moderate cases<sup>71</sup>. One specific mechanism is increased brain interferon-induced 505 transmembrane protein (IFITM1-3) expression triggered by viral infection. Increased 506 incorporation of IFITM3 into the g-secretase complex potentiates its activity, increasing Aß 507 production <sup>72,73</sup>.

#### 508

The AD biomarker proteins studied here are being increasingly assessed at scale<sup>24,74</sup>, but
their patterns of their variation in the general population are not fully characterised. Aβ and
pTau are strongly linked to AD and neurodegeneration, but they can vary with specific
conditions other than AD<sup>87</sup>. In the present dataset, concentrations of these proteins showed
associations with a variety of traits including hypertension, weight, GFR and Type II Diabetes
diagnosis. However, the observed SARS-CoV-2 infection-related effects remained when
these factors were included in the model as potential confounders.

516

517 In addition to highlighting increased plasma biomarkers of prodromal AD with SARS-CoV-2 518 infection, application of the more general Olink plasma protein-based risk scores developed 519 in an earlier UK Biobank study also provides evidence for greater predicted risks for 520 diabetes, ischaemic stroke and heart disease. COPD, lung cancer and endometriosis in the subset of participants under the age of 73<sup>20</sup>. This is consistent with emerging post-COVID-521 19 epidemiology data <sup>76–79</sup> and proteomic studies of samples from COVID-19 patients 522 hospitalised with acute symptoms<sup>19</sup>. While we found limited evidence for comorbidities 523 524 directly confounding our AD biomarker observations, the raised risk of many - albeit not all -525 diseases with SARS-CoV-2 infection raises the possibility that SARS-CoV-2 (and other 526 infections) may accelerate both body and brain aging <sup>82</sup>. The changes in these risk-markers 527 across diseases may be due to common (e.g., inflammation) processes initiated with SARS-528 CoV-2 infection, a hypothesis supported by findings of associations of Alzheimer's disease with multiple co-morbidities<sup>88</sup>. It is likely that infections can have both general and specific 529 impacts on disease risks, and will affect different organ systems<sup>1,23</sup>. 530

531

532 Patients with hepatic dysfunction have raised levels of plasma beta-amyloids and increased Aβ42/40 ratios<sup>82,83</sup>. However, this is opposite to the direction of change observed here. We 533 534 also did not find evidence for increases in Olink protein signatures associated with hepatic 535 dysfunction after SARS-CoV-2. Kidney function can also affect plasma protein levels. We 536 identified associations between eGFR and protein levels, but these did not confound our 537 primary results. Increased plasma pTau-181 is associated with combined peripheral and 538 central nerve pathology in ALS and with spinal muscular atrophy<sup>76</sup>. While further research is 539 necessary<sup>77</sup>, we believe that the association of both increased plasma pTau-181 and 540 decreased plasma beta-amyloid 42/40 ratios with SARS-CoV-2 infection most likely reflects 541 brain pathology.

542

543 While our study was able to combine fluid biomarkers, imaging data, cognitive performance, 544 and other covariates in a longitudinal case-control design, it has limitations. We relied on 545 data linkage to hospital records and retrospective reports for information concerning 546 symptoms associated with SARS-CoV-2 infections, limiting our ability to investigate detailed 547 relationships between the clinical severity of infections and plasma biomarker changes. 548 While we used prospectively acquired samples from before and after SARS-CoV-2 infection, 549 the pragmatic, observational nature of our analyses precludes making strong causal 550 inferences. While case and control groups were well matched by most measures (including 551 cognitive scores, inflammation markers and disease risks), there were some differences 552 variables in body mass, activity levels, and diabetes mellitus and hypertension rates. While 553 analyses controlled for these and other known risk factors, it is possible there are additional, 554 uncontrolled susceptibility factors that distinguished the SARS-CoV-2 infection and control 555 groups. Asymptomatic cases may be under-represented in the sample. This does not

556 invalidate the assessment of accelerated changes in biomarkers in the current sample 557 relative to baseline levels, but it means that these changes may be lower in the broader 558 population. Generalisation of our results to the wider population must be done with care: the 559 UK Biobank sample population is not representative of the general population by many measures<sup>83</sup>. 560 561 562 Recent studies have compared various blood phosphorylated tau immunoassays, notably those measuring pTau-217 and -231, for their utility as biomarkers for AD<sup>84</sup>. In head-to-563 head assays, all were able to identify AD and brain AB pathology<sup>85</sup>. pTau-217 has shown a 564 565 greater sensitivity to later-stage disease progression, but pTau-231 and pTau-181 may show 566 greater sensitivity to early stage amyloid accumulation, the primary disease phase of interest here 87,88. 567 568 In conclusion, our study, along with earlier studies suggesting increased rates of dementia 569 diagnosis following COVID-19<sup>89</sup>, suggests that public health planning should take into 570 571 account the possibility of increased rates of AD (and other systemic diseases) in the coming 572 years due to the COVID-19 pandemic. Moreover, the relationships described here are 573 unlikely to be specific for SARS-CoV-2 and may reflect more general effects of systemic viral 574 or other infections on the aging brain. This highlights the need to prioritise pandemic 575 preparedness as part of a strategy for reducing the future long-term burden of dementia and 576 other chronic diseases, as well as for the direct impact of the acute infections. 577

# 578 Online Methods

#### 579 Ethics

580 The UK Biobank is approved by the North West Multi-Centre Research Ethics Committee 581 (MREC) to obtain and share data and samples from volunteer participants. Written informed 582 consent was obtained from all participants (http://www.ukbiobank.ac.uk/ethics/).

#### 583 Design

584

585 This study analyses Simoa ultra-sensitive assays of dementia-related proteins taken from blood-plasma obtained from participants in the UK Biobank COVID-19 repeat imaging 586 587 study)<sup>10</sup>. This study identified case and control participants from those who had taken part in the UK Biobank imaging enhancement<sup>90</sup>, which comprises a comprehensive imaging 588 589 assessment at one of four dedicated sites. Over 40,000 participants had been assessed 590 prior to the COVID-19 pandemic. Inclusion criteria and other details are described in 591 https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/casecontrol covidimaging.pdf. 592 593 Participants were identified as being SARS-CoV-2-positive by the UK Biobank if (a) there

- 594 were positive diagnostic antigen tests identified in the linkage to health-related records, (b)
- 595 COVID-19 was reported in their primary care data or hospital records, or (c) two home-
- 596 based lateral-flow antibody tests provided by the UK Biobank were positive (Fortress Fast

597 COVID-19 Home test, Fortress Diagnostics and ABC-19TM Rapid Test, Abingdon Health).
598 Both diagnostic antigen test and GP/hospital records were accompanied by data permitting
599 estimation of date of COVID-19 infection.

600

601 In all, Simoa biomarker measurements from 626 cases and their matched controls were 602 available. Each participant had biomarker measurements from blood samples taken 603 longitudinally from the two imaging assessment sessions (pre- and post-pandemic). 604 Complete pairs of these data were available from 600 cases and from the 600 their matched 605 controls had complete data. For the 626 cases, SARS-CoV-2 infection was determined from 606 mixed sources: 358 had a general practitioner's diagnosis of COVID-19, 438 had record of a 607 positive diagnostic antigen test prior to the assessment, and 467 returned positive on home-608 based antibody lateral flow test kits (Fig 1b). 24 participants had SARS-CoV-2 infection 609 determined during a period of hospitalisation, for which 20 had COVID-19 listed as a primary cause. Two participants were excluded for having a prior dementia diagnosis (vascular 610 611 dementia), identified from hospital inpatient records. 612

Control participants were selected as those who had negative antibody test results, and / or
no other record of confirmed or suspected COVID-19 from available data. Control
participants were matched to positive cases based on five characteristics: sex, ethnicity
(non-white/white), date of birth (+/- 6 months), the location of first imaging assessment, and
the date of this assessment (+/- 6 months). Further details of case and control identification
are provided in the above link and <sup>10</sup>.

#### 620 Proteomic assay acquisition and pre-processing

Aβ40, Aβ42, NfL and GFAP concentrations were measured using the Simoa Human
Neurology 4-Plex E assay (Quanterix). The Simoa P-tau181 Advantage Kit was used to
measure P-tau181 concentration. All measurements were made on an HD-X instrument
(Quanterix) with one round of experiments and a single batch of reagents. Technicians were
blinded to participant case-control status and from which assessment visit a sample was
taken from. Measurements were all above limit of detection and coefficients of variation
within analytes were below 10%.

628

629 Anonymised data from 1256 participants were integrated with phenotype data via a UK 630 Biobank key. Four participants were excluded for data being only available for one of the 631 two imaging sessions. P-tau181, NfL, and GFAP markers showed positively skewed 632 distributions and were log-normalised. For each biomarker, outliers were identified as 633 measurements more than 8 times the Median Absolute Deviation (MAD) and excluded from 634 the analysis. PCR plate IDs were also regressed out from the data. There was no 635 significant imbalance of outliers or plate IDs across cases and controls. Cases and controls 636 were matched according to UK Biobank field 4100 with 609 case-control pairs identified. 637 1220 participants and 583 matched case-control pairs had complete proteomic data. All 638 analyses were performed on matched data, except (as noted) when key covariates of 639 interest were missing from a set of participants. The Simoa Neurology assays showed 640 patterns of covariance across participants closely matching previous reports (Fig 5) 91. 641

### 642 Olink Proteomics

643

644 We used Olink Explore proteomic data from the Pharma Proteomics Project (PPP) which 645 assayed samples from 54,219 UK Biobank participants across the different assessment 646 sessions <sup>35</sup>. Available data from the COVID-19 imaging assessment sessions for our 647 case/control matched pairs comprised 436 matched participant pairs for which 1474 proteins 648 from Cardiometabolic, Inflammation, Neurology and Oncology Olink panels were assayed. 649 The Olink 3072 Explore platform extension data were not available for this COVID-19 case-650 control matched assessment visits. Available Olink proteins included NFL and GFAP which 651 were also profiled in the Simoa assays. These markers were positively correlated to their 652 Simoa counterparts (r=0.70 and 0.53 respectively).

653

654 The Olink panel included Cystatin-C, which permitted estimation of the Glomerular Filtration 655 Rate (eGFR) in the imaging assessment sessions using the KD-EPI Cystatin C Equation<sup>92</sup>. 656 We first assessed how well protein levels measured by OLINK related to serum Cystatin-C 657 measurements made separately and included in the UK Biobank core blood biochemistry 658 panel data. The latter were derived from the Siemens Advia 1800 platform protein and 659 available only for the initial UK Biobank assessment session. OLINK Cystatin-C measures 660 in our study baseline plasma samples and those from earlier plasma samples acquired on 661 the same participants showed a correlation of 0.84, which was used for appropriate rescaling 662 of the OLINK data to enable eGFR estimation from the OLINK data.

663

We assessed 13 inflammatory proteins identified from a literature search of associations of
inflammatory proteins in blood or CSF with COVID and/or Alzheimer's disease
(Supplementary table 14). The inflammatory proteins and risk scores were analysed for
baseline case-control differences and associations with AD proteins change using the
statistical models outlined below.

669

670 We also investigated whether recently defined multivariate plasma protein concentration 671 changes associated with disease risk (ProteinScores) derived from Olink Explore plasma 672 protein biomarkers in 47,600 UK biobank participants<sup>20</sup> provided evidence for increased 673 systemic chronic disease risks following SARS-CoV-2 infection. These scores were derived 674 using penalised Cox elastic net regression which linked protein levels some samples in the 675 initial UK Biobank assessment session to over 16 years of primary and secondary care NHS 676 records disclosing 21 incident outcomes. Being penalised regression, each score comprises 677 weights from 10-20 Olink proteins, selection of which was validated using hold-out data from 678 the UK Biobank. As these risk scores were derived and validated on participants below the 679 age of 73 years, we limited our analysis to this subset of our case-control cohort (i.e., the 680 353 cases and 353 matched controls under the age of 73).

681

We generated these risk scores for protein profile data from the COVID-19 imagingassessment sessions. The data were rank-base inverse normal transformed and rescaled to

684 match the processing applied in the generation of the ProteinScores. Disease weight scores 685 were downloaded from the publication website and applied to the data<sup>20</sup>.

### 686 Phenotypic data processing

687 Primary data for the study comes from the two imaging assessment sessions. Genetic and

688 phenotypic data, including imaging and health records were available for all participants who

took part in the COVID-19 reimaging project. Symptomology analyses used data from the

690 UK Biobank COVID-19 Serology Study<sup>93</sup>. Data were parsed and cleaned using the FMRIB

- 691 UK Biobank Normalisation, Parsing and Cleaning Kit, and integrated with other data
- 692 modalities into a combined Python pandas data frame.

### 693 Genetics

694 APOE variant status was extracted from UK Biobank subject genotyping using PLINK-2.0<sup>94</sup>.

695 We extracted variants at SNPs *rs429358* and *rs7412* to identify participants' *APOE* status.

697 (135),  $\epsilon 4 \epsilon 4$  (20), and  $\epsilon 2 \epsilon 2 (7)$ . We used  $\epsilon 3 \epsilon 3$  genotype as reference when one was required.

698 Additional AD and COVID-19 -associated single nucleotide polymorphisms in the UK

699 Biobank dataset were sequenced directly or imputed.

### <sup>700</sup> Imaging data and neuroimaging AD phenotype score

701 To avoid the multiple testing challenge of large numbers of neuroimaging measures and 702 provide a measure recognised to be relevant to AD, we estimated a structural brain data AD 703 phenotype score for each participant at each assessment session using structural brain imaging-derived measures made available through the UK Biobank Showcase<sup>95,96</sup>. The AD 704 705 phenotype score, developed on the Alzheimer's Disease Neuroimaging Initiative (ADNI) 706 dataset, reflects the prediction of a Bayesian machine learning neural that a participant has 707 AD from 155 FreeSurfer cortical volume and thickness measures<sup>41</sup>. Monte Carlo dropout 708 was used to approximate Bayesian inference within a two-layer neural network. This 709 phenotype model was trained on 736 individuals (331 AD) from the ADNI database, and 710 validated on 5209 participants from the National Alzheimer's Coordinating Centre and 37,104 participants in the UK Biobank<sup>41</sup>, where predicted at-risk participants showed 711

- 712 cognitive profiles representative of AD.
- 713

714 Neuroimaging measures contributing to the AD phenotype were processed using the same

- 715 steps as used for the generation of the model. Each cortical volume and thickness
- 716 measures was cleaned by removing outliers more extreme than eight times the median
- 717 absolute deviation from the median (across both pre-pandemic and pandemic assessment
- visits). The measures were then de-confounded for age, estimated total intracranial volume,

and sex, and rescaled using normalisation statistics from the ADNI training set. Software to

- 720 generate these signatures was downloaded from
- https://github.com/tjiagoM/adni\_phenotypes . PyTorch was used to apply the trained model
   (https://wandb.ai/tjiagom/adni\_phenotypes/runs/2cxy59fk) to UK Biobank data.

### 723 Cognitive Scores

725 The UK Biobank includes a series of standard cognitive tests, but they can be individually

unreliable, and do not together correspond to established tests for general or dementia-

related cognitive scoring. A procedure to estimate a measure of general cognitive ability

from the UK Biobank data has previously been developed using an external validation

dataset <sup>49</sup>. We used the resulting score weights to calculate an overall score for cognitive

ability for participants in each assessment visit.

#### 731 Statistical modelling

732 We assessed longitudinal change in proteomic biomarkers and the effect of SARS-CoV-2 on 733 this change using linear models which modelled protein levels in the pandemic assessment 734 samples in terms of the pre-pandemic protein concentrations, the time between assessment 735 visits, designation as a case or control and potential confounders including age and baseline 736 differences genetic backgrounds, sex, health status or social risk factors for COVID between cases and controls<sup>10</sup>. We approached this is a staged fashion that allowed the impact of 737 738 confounder covariates (some which were available only in a proportion of subjects) to be 739 understood. Our basic model included covariates for Sex, Age, and the interval between 740 assessments:

741

742 Protein\_post = Protein\_pre + Interval\_between\_assessments +

743 Interval\_between\_assessments^2 + Case/control + Genetic\_sex + Age\_post744

The extended models included further variables known or expected to change over the
assessment period and with COVID-19 (Table 4). Some variables presented considerable
missing data, such that the extended models had reduced power.

748

749 As the impact of SARS-CoV-2 infection is expected to vary according to certain 750 characteristics and vulnerabilities, we fit further models including interaction terms modelling 751 the interaction of SARS-CoV-2 status with characteristics including APOE status. 752 hospitalisation, and pre-pandemic neuroimaging AD score, to determine if these factors 753 modified the effect of SARS-CoV-2 on protein levels. Age is an important vulnerability 754 factor. Past modelling studies of brain structural changes associated with COVID-19 have 755 used a score of age-dependent vulnerability as an interaction term to account for the greater vulnerability of the brain with age<sup>10</sup>. An exponential age-dependent vulnerability score term 756  $(10^{Age_{x-0.0524}--3.27})$  was derived from the modelling of the observed relationship between 757 age and COVID-19 neurological symptom severity<sup>37</sup>. All these interaction models included 758 759 both the original case-control variable and the original vulnerability terms in addition to the 760 interaction term, along with additional covariates used in the basic model.

761

In addition to protein levels, we modelled several additional outcome measures: disease risk scores, a general cognitive ability score, a neuroimaging AD score, and reported level of general health. These outcomes were modelled in the same manner as the protein levels above. To assess whether changes in these outcomes were associated with changes in protein scores, additional models were assessed which included as predictors the prepandemic levels of proteins and their change across assessment visits. Linear models were also used to assess relationships between protein levels and UK Biobank variables at

baseline. Age, sex, and interval between assessments were used as confound variables inthese models as above.

771

The models were fit using Ordinary Least Squares and tested model parameters using t-

tests. As we had strong hypotheses regarding direction of SARS-CoV-2-induced change in

AD protein levels based on prior literature, we used one-sided tests. Benjamini/Hochberg

False Discovery Rate with alpha=0.05 was used to control for statistical testing of multiple

776 hypothesis across proteins and/or covariates.

# 777 Data and code availability

- All data is available upon application from the UK Biobank.
- 779

780 Code for analyses and figures will be shared from the UKDRI GitHub page.

781

# 782 Acknowledgements

783 This research has been conducted using the UK Biobank Resource under Application 784 Number 76059. We are grateful to the participants, researchers, and all UK Biobank staff for 785 their contributions to enabling this research. We particularly acknowledge the efforts of the 786 staff and the commitment of UK Biobank participants to allowing the acquisition of these data 787 during the COVID-19 pandemic. We also want to acknowledge support for the conception, 788 development, funding and interpretation of results of the study from Dr. Sally Johns of 789 Biogen. We thank the anonymous reviewers for their valuable suggestions. Figures were 790 created with BioRender.com.

791

792 EPD is supported jointly by funding to PMM from the UK Dementia Research Institute and 793 from the NIHR Imperial Biomedical Research Centre, in which he is a member of the 794 Multiple Long-Term Conditions theme. HZ is a Wallenberg Scholar supported by grants 795 from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the 796 European Union's Horizon Europe research and innovation programme under grant 797 agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), 798 the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD 799 Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-800 C, and #ADSF-21-831377-C), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon 801 Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, 802 Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and 803 innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 804 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research 805 (JPND2021-00694), the National Institute for Health and Care Research University College 806 London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at 807 UCL (UKDRI-1003). PMM acknowledges generous personal support from the Edmond J 808 Safra Foundation and Lily Safra and an NIHR Senior Investigator Award. His work 809 additionally is supported by the UK Dementia Research Institute, which receives its funding

810 from UK DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society and

811 Alzheimer's Research UK and, for this research specifically, Biogen.

812

# **Competing interests**

814 HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, 815 Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito 816 Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, 817 Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, 818 Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in 819 symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a 820 co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU 821 Ventures Incubator Program (outside submitted work). PMM is a consultant for Biogen, Sudo 822 Therapeutics, Nimbus, Astex, GSK and Sangamo. He received research funding for aspects 823 of this work from Biogen and the UK DRI. He has research funding unrelated to this work 824 from Biogen and Bristol Meyers Squibb. 825

# 826 **References**

- 1. Levine, K. S. et al. Virus exposure and neurodegenerative disease risk across national
- 829 biobanks. Neuron 111, 1086-1093.e2 (2023).
- 830 2. Ou, Y.-N. et al. Associations of Infectious Agents with Alzheimer's Disease: A Systematic
- 831 Review and Meta-Analysis. *Journal of Alzheimer's Disease* **75**, 299–309 (2020).
- 3. Muzambi, R. et al. Assessment of common infections and incident dementia using UK
- primary and secondary care data: a historical cohort study. *The Lancet Healthy*
- 834 *Longevity* **2**, e426–e435 (2021).
- 4. Muzambi, R. et al. Are infections associated with cognitive decline and neuroimaging
- 836 outcomes? A historical cohort study using data from the UK Biobank study linked to
- electronic health records. *Transl Psychiatry* **12**, 1–11 (2022).
- 5. Debisarun, P. A. *et al.* Induction of trained immunity by influenza vaccination impact on
- 839 COVID-19. *PLOS Pathogens* **17**, e1009928 (2021).

- 840 6. Franceschi, C. & Campisi, J. Chronic Inflammation (Inflammaging) and Its Potential
- 841 Contribution to Age-Associated Diseases. *The Journals of Gerontology: Series A* 69,
- 842 S4–S9 (2014).
- 7. Tejera, D. *et al.* Systemic inflammation impairs microglial Aβ clearance through NLRP3
- inflammasome. The EMBO Journal **38**, e101064 (2019).
- 845 8. Hosseini, S., Michaelsen-Preusse, K., Schughart, K. & Korte, M. Long-Term
- 846 Consequence of Non-neurotropic H3N2 Influenza A Virus Infection for the Progression
- 847 of Alzheimer's Disease Symptoms. *Frontiers in Cellular Neuroscience* **15**, (2021).
- 9. Xu, E., Xie, Y. & Al-Aly, Z. Long-term neurologic outcomes of COVID-19. Nat Med 28,
- 849 2406–2415 (2022).
- 10. Douaud, G. et al. SARS-CoV-2 is associated with changes in brain structure in UK
- Biobank. *Nature* **604**, 697–707 (2022).
- 11. Hampshire, A. *et al.* Cognitive deficits in people who have recovered from COVID-19. *eClinicalMedicine* **39**, (2021).
- 12. Hampshire, A. et al. Cognition and Memory after Covid-19 in a Large Community
- 855 Sample. *N Engl J Med* **390**, 806–818 (2024).
- 13. Shan, D., Wang, C., Crawford, T. & Holland, C. Temporal Association between COVID-
- 857 19 Infection and Subsequent New-Onset Dementia in Older Adults: A Systematic
- 858 Review and Meta-Analysis. SSRN Scholarly Paper at
- 859 https://doi.org/10.2139/ssrn.4716751 (2024).
- 860 14. Xie, J. et al. Low-grade peripheral inflammation affects brain pathology in the AppNL-G-
- 861 Fmouse model of Alzheimer's disease. *acta neuropathol commun* **9**, 163 (2021).
- 15. Yang, A. C. et al. Dysregulation of brain and choroid plexus cell types in severe COVID-
- 863 19. *Nature* **595**, 565–571 (2021).
- 16. Taquet, M., Geddes, J. R., Husain, M., Luciano, S. & Harrison, P. J. 6-month
- 865 neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a
- 866 retrospective cohort study using electronic health records. The Lancet Psychiatry 8,
- 867 416–427 (2021).

- 868 17. Zetterberg, H. & Blennow, K. Moving fluid biomarkers for Alzheimer's disease from
- 869 research tools to routine clinical diagnostics. *Molecular Neurodegeneration* **16**, 10

870 (2021).

- 18. Saunders, T. S. et al. Predictive blood biomarkers and brain changes associated with
- age-related cognitive decline. *Brain Communications* **5**, fcad113 (2023).
- 19. Wang, L. et al. Plasma proteomics of SARS-CoV-2 infection and severity reveals impact
- on Alzheimer's and coronary disease pathways. *iScience* **26**, (2023).
- 20. Gadd, D. A. et al. Blood protein levels predict leading incident diseases and mortality in
- 876 UK Biobank. 2023.05.01.23288879 Preprint at
- 877 https://doi.org/10.1101/2023.05.01.23288879 (2023).
- 21. Carrasco-Zanini, J. *et al.* Proteomic prediction of common and rare diseases.
- 879 2023.07.18.23292811 Preprint at https://doi.org/10.1101/2023.07.18.23292811 (2023).
- 880 22. You, J. et al. Plasma proteomic profiles predict individual future health risk. Nat Commun
- **14**, 7817 (2023).
- 882 23. Oh, H. S.-H. et al. Organ aging signatures in the plasma proteome track health and
- 883 disease. *Nature* **624**, 164–172 (2023).
- 24. Jia, J. *et al.* Biomarker Changes during 20 Years Preceding Alzheimer's Disease. *New*
- 885 England Journal of Medicine **390**, 712–722 (2024).
- 25. Janelidze, S. et al. Plasma P-tau181 in Alzheimer's disease: relationship to other
- 887 biomarkers, differential diagnosis, neuropathology and longitudinal progression to
- 888 Alzheimer's dementia. *Nat Med* **26**, 379–386 (2020).
- 26. Baldeiras, I. *et al.* Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker
- 890 profile increases the predictive value for underlying Alzheimer's disease dementia in mild
- cognitive impairment. *Alzheimer's Research & Therapy* **10**, 33 (2018).
- 892 27. Fandos, N. et al. Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral
- deposition in cognitively normal individuals. Alzheimers Dement (Amst) 8, 179–187
- 894 (2017).

- 28. Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing
- amyloid deposition in Alzheimer's disease. *EMBO Molecular Medicine* **11**, e11170
- 897 (2019).
- 29. Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & for the Alzheimer's
- 899 Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With
- 900 Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology 74, 557–566
- 901 (2017).
- 30. Kim, K. Y., Shin, K. Y. & Chang, K.-A. GFAP as a Potential Biomarker for Alzheimer's
- 903 Disease: A Systematic Review and Meta-Analysis. *Cells* **12**, 1309 (2023).
- 31. Lai, Y.-J. *et al.* Biomarkers in long COVID-19: A systematic review. *Frontiers in Medicine*10, (2023).
- 906 32. Frontera, J. A. et al. Comparison of serum neurodegenerative biomarkers among
- 907 hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild
- 908 cognitive impairment, or Alzheimer's dementia. *Alzheimers Dement* **18**, 899–910 (2022).
- 33. Williams, S. A. et al. Plasma protein patterns as comprehensive indicators of health. Nat
- 910 *Med* **25**, 1851–1857 (2019).
- 911 34. Lindbohm, J. V. et al. Plasma proteins, cognitive decline, and 20-year risk of dementia in
- 912 the Whitehall II and Atherosclerosis Risk in Communities studies. Alzheimer's &
- 913 Dementia **18**, 612–624 (2022).
- 35. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK
  Biobank. *Nature* 622, 329–338 (2023).
- 916 36. Schindler, S. E. *et al.* High-precision plasma β-amyloid 42/40 predicts current and future
- 917 brain amyloidosis. *Neurology* **93**, e1647–e1659 (2019).
- 918 37. Levin, A. T. *et al.* Assessing the age specificity of infection fatality rates for COVID-19:
- 919 systematic review, meta-analysis, and public policy implications. *European Journal of*
- 920 *Epidemiology* **35**, 1123 (2020).

- 921 38. Stocker, H. et al. Association of Kidney Function With Development of Alzheimer
- 922 Disease and Other Dementias and Dementia-Related Blood Biomarkers. JAMA Network
- 923 Open **6**, e2252387 (2023).
- 39. Gallo, G., Calvez, V. & Savoia, C. Hypertension and COVID-19: Current Evidence and
- 925 Perspectives. *High Blood Press Cardiovasc Prev* **29**, 115–123 (2022).
- 40. Biskaduros, A. et al. Longitudinal trajectories of Alzheimer's disease CSF biomarkers
- 927 and blood pressure in cognitively healthy subjects. *Alzheimer's & Dementia* **n/a**,.
- 41. Camerlingo, C. Vaccination to reduce severe COVID-19 and mortality in COVID-19
- 929 patients: a systematic review and meta-analysis. European Review
- 930 https://www.europeanreview.org/article/28248 (2022).
- 42. Safdari Lord, J., Soltani Rezaiezadeh, J., Yekaninejad, M. S. & Izadi, P. The association
- of APOE genotype with COVID-19 disease severity. *Sci Rep* **12**, 13483 (2022).
- 43. Azevedo, T. et al. Identifying healthy individuals with Alzheimer neuroimaging
- 934 phenotypes in the UK Biobank. 2022.01.05.22268795 Preprint at
- 935 https://doi.org/10.1101/2022.01.05.22268795 (2022).
- 936 44. Klyucherev, T. O. et al. Advances in the development of new biomarkers for Alzheimer's
- 937 disease. *Transl Neurodegener* **11**, 25 (2022).
- 938 45. Vergallo, A. et al. Association of plasma YKL-40 with brain amyloid-β levels, memory
- 939 performance, and sex in subjective memory complainers. *Neurobiology of Aging* 96, 22–
  940 32 (2020).
- 46. Lennol, M. P. *et al.* Transient Changes in the Plasma of Astrocytic and Neuronal Injury
  Biomarkers in COVID-19 Patients without Neurological Syndromes. *Int J Mol Sci* 24,
- 943 2715 (2023).
- 944 47. Byeon, S. K. et al. Development of a multiomics model for identification of predictive
- biomarkers for COVID-19 severity: a retrospective cohort study. *Lancet Digit Health* 4,
  e632–e645 (2022).
- 947 48. Gaudet, L. A. et al. Associations between SARS-CoV-2 infection and incidence of new
- 948 chronic condition diagnoses: a systematic review. *Emerg Microbes Infect* **12**, 2204166.

- 949 49. Fawns-Ritchie, C. & Deary, I. J. Reliability and validity of the UK Biobank cognitive tests.
- 950 PLOS ONE 15, e0231627 (2020).
- 951 50. Atchison, C. J. et al. Long-term health impacts of COVID-19 among 242,712 adults in
- 952 England. *Nat Commun* **14**, 6588 (2023).
- 953 51. Mizrahi, B. *et al.* Long covid outcomes at one year after mild SARS-CoV-2 infection:
- 954 nationwide cohort study. *BMJ* **380**, e072529 (2023).
- 955 52. Boulo, S. et al. First amyloid β1-42 certified reference material for re-calibrating
- 956 commercial immunoassays. *Alzheimer's & Dementia* **16**, 1493–1503 (2020).
- 957 53. Virhammar, J. et al. Biomarkers for central nervous system injury in cerebrospinal fluid
- 958 are elevated in COVID-19 and associated with neurological symptoms and disease
- 959 severity. European Journal of Neurology 28, 3324–3331 (2021).
- 960 54. Therriault, J. et al. Association of Phosphorylated Tau Biomarkers With Amyloid Positron
- 961 Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol 80, 188–
- 962 199 (2023).
- 963 55. van Arendonk, J. et al. Plasma neurofilament light chain in relation to 10-year change in
- 964 cognition and neuroimaging markers: a population-based study. *GeroScience* (2023)
- 965 doi:10.1007/s11357-023-00876-5.
- 966 56. O'Connor, A. et al. Plasma GFAP in presymptomatic and symptomatic familial
- 967 Alzheimer's disease: a longitudinal cohort study. *J Neurol Neurosurg Psychiatry* 94, 90–
  968 92 (2023).
- 57. Diray-Arce, J. *et al.* Multi-omic longitudinal study reveals immune correlates of clinical
  course among hospitalized COVID-19 patients. *CR Med* 4, (2023).
- 971 58. Zhang, X., Fu, Z., Meng, L., He, M. & Zhang, Z. The Early Events That Initiate β-Amyloid
  972 Aggregation in Alzheimer's Disease. *Front Aging Neurosci* **10**, 359 (2018).
- 973 59. Abbott, A. Are infections seeding some cases of Alzheimer's disease? *Nature* 587, 22–
  974 25 (2020).
- 975 60. Mawanda, F., Wallace, R. B., McCoy, K. & Abrams, T. E. Systemic and localized extra-
- 976 central nervous system bacterial infections and the risk of dementia among US veterans:

- 977 A retrospective cohort study. Alzheimer's & Dementia: Diagnosis, Assessment &
- 978 Disease Monitoring **4**, 109–117 (2016).
- 979 61. Sipilä, P. N. et al. Hospital-treated infectious diseases and the risk of dementia: a large,
- 980 multicohort, observational study with a replication cohort. The Lancet Infectious
- 981 Diseases **21**, 1557–1567 (2021).
- 982 62. Radke, J. et al. Proteomic and transcriptomic profiling of brainstem, cerebellum and
- 983 olfactory tissues in early- and late-phase COVID-19. *Nat Neurosci* 27, 409–420 (2024).
- 984 63. Gordon, M. N. et al. Impact of COVID-19 on the Onset and Progression of Alzheimer's
- 985 Disease and Related Dementias: A Roadmap for Future Research. Alzheimer's &
- 986 *Dementia* **18**, 1038–1046 (2022).
- 987 64. Walker, K. A. et al. The role of peripheral inflammatory insults in Alzheimer's disease: a
- 988 review and research roadmap. *Molecular Neurodegeneration* **18**, 37 (2023).
- 989 65. Jorfi, M., Maaser-Hecker, A. & Tanzi, R. E. The neuroimmune axis of Alzheimer's
  990 disease. *Genome Med* 15, 6 (2023).
- 66. Holmes, C. *et al.* Systemic inflammation and disease progression in Alzheimer disease.
- 992 *Neurology* **73**, 768–774 (2009).
- 993 67. Morgan, D. G. & Mielke, M. M. Knowledge gaps in Alzheimer's disease immune
- biomarker research. *Alzheimer's & Dementia* **17**, 2030–2042 (2021).
- 995 68. Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N. & LaFerla, F. M.
- 996 Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-
- 997 Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease.
- 998 *J. Neurosci.* **25**, 8843–8853 (2005).
- 999 69. Walker, K. A. et al. Midlife systemic inflammatory markers are associated with late-life
- 1000 brain volume: The ARIC study. *Neurology* **89**, 2262 (2017).
- 1001 70. Jacob, F. et al. Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids
- 1002 Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium. Cell
- 1003 Stem Cell **27**, 937-950.e9 (2020).

- 1004 71. Phetsouphanh, C. et al. Immunological dysfunction persists for 8 months following initial
- 1005 mild-to-moderate SARS-CoV-2 infection. *Nat Immunol* **23**, 210–216 (2022).
- 1006 72. Hur, J.-Y. et al. The innate immunity protein IFITM3 modulates γ-secretase in
- 1007 Alzheimer's disease. *Nature* **586**, 735–740 (2020).
- 1008 73. Gholami, M. et al. Interferon-Induced Transmembrane Protein 3 rs34481144 C/T
- 1009 Genotype and Clinical Parameters Related to Progression of COVID-19. J Immunol Res
- 1010 **2023**, 2345062 (2023).
- 1011 74. Ashton, N. J. et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217
- 1012 Immunoassay for Alzheimer Disease Pathology. *JAMA Neurol* **81**, 255–263 (2024).
- 1013 75. Janelidze, S. et al. Plasma β-amyloid in Alzheimer's disease and vascular disease. Sci
- 1014 *Rep* **6**, 26801 (2016).
- 1015 76. Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19.
- 1016 Nat Med 28, 583–590 (2022).
- 1017 77. Wan, E. Y. F. et al. Association of COVID-19 with short- and long-term risk of
- 1018 cardiovascular disease and mortality: a prospective cohort in UK Biobank.
- 1019 *Cardiovascular Research* **119**, 1718–1727 (2023).
- 1020 78. Marín, J. S. et al. Increased incidence of rheumatoid arthritis after COVID-19.
- 1021 *Autoimmunity Reviews* **22**, 103409 (2023).
- 1022 79. Rathmann, W., Kuss, O. & Kostev, K. Incidence of newly diagnosed diabetes after
- 1023 Covid-19. *Diabetologia* **65**, 949–954 (2022).
- 1024 80. Argentieri, M. A. et al. Proteomic aging clock predicts mortality and risk of common age-
- 1025 related diseases in diverse populations. 2023.09.13.23295486 Preprint at
- 1026 https://doi.org/10.1101/2023.09.13.23295486 (2023).
- 1027 81. Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the
- 1028 Lancet Commission. *The Lancet* **396**, 413–446 (2020).
- 1029 82. Wang, Y.-R. et al. Associations Between Hepatic Functions and Plasma Amyloid-Beta
- 1030 Levels-Implications for the Capacity of Liver in Peripheral Amyloid-Beta Clearance. *Mol*
- 1031 *Neurobiol* **54**, 2338–2344 (2017).

- 1032 83. Lyu, H. et al. Plasma amyloid-beta levels correlated with impaired hepatic functions: An
- 1033 adjuvant biomarker for the diagnosis of biliary atresia. *Front. Surg.* **9**, (2022).
- 1034 84. Cousins, K. A. Q. et al. Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral
- 1035 Sclerosis. Annals of Neurology **92**, 807–818 (2022).
- 1036 85. Vacchiano, V. et al. Elevated plasma p-tau181 levels unrelated to Alzheimer's disease
- 1037 pathology in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 94, 428–435
- 1038 (2023).
- 1039 86. Schoeler, T. et al. Participation bias in the UK Biobank distorts genetic associations and
- 1040 downstream analyses. *Nat Hum Behav* **7**, 1216–1227 (2023).
- 1041 87. Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in
- 1042 prodromal Alzheimer's disease. *Brain* **146**, 1592–1601 (2022).
- 1043 88. Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head
- 1044 comparison of phosphorylated tau immunoassays. *Alzheimer's & Dementia* 19, 1913–
  1045 1924 (2023).
- 1046 89. Wang, L. et al. Association of COVID-19 with New-Onset Alzheimer's Disease. J
- 1047 *Alzheimers Dis* **89**, 411–414 (2022).
- 1048 90. Littlejohns, T. J. *et al.* The UK Biobank imaging enhancement of 100,000 participants:
- 1049 rationale, data collection, management and future directions. *Nature Communications*
- **1050 11**, 2624 (2020).
- 1051 91. Stevenson-Hoare, J. et al. Plasma biomarkers and genetics in the diagnosis and
- 1052 prediction of Alzheimer's disease. *Brain* **146**, 690–699 (2023).
- 1053 92. Inker Lesley A. et al. Estimating Glomerular Filtration Rate from Serum Creatinine and
- 1054 Cystatin C. New England Journal of Medicine **367**, 20–29 (2012).
- 1055 93. Bešević, J. et al. Persistence of SARS-CoV-2 antibodies over 18 months following
- 1056 infection: UK Biobank COVID-19 Serology Study. *J Epidemiol Community Health* (2023)
- 1057 doi:10.1136/jech-2023-220569.
- 1058 94. Second-generation PLINK: rising to the challenge of larger and richer datasets |
- 1059 GigaScience | Oxford Academic.

1060 https://academic.oup.com/gigascience/article/4/1/s13742-015-0047-

1061 8/2707533?login=false.

- 1062 95. Miller, K. L. *et al.* Multimodal population brain imaging in the UK Biobank prospective
- 1063 epidemiological study. *Nature Neuroscience* **19**, 1523–1536 (2016).
- 1064 96. Alfaro-Almagro, F. et al. Image processing and Quality Control for the first 10,000 brain
- 1065 imaging datasets from UK Biobank. *NeuroImage* **166**, 400–424 (2018).
- 1066 97. Makaremi, S. *et al.* The role of IL-1 family of cytokines and receptors in pathogenesis of

1067 COVID-19. Inflamm. Res. **71**, 923–947 (2022).

- 1068 98. Dursun, E. et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-
- 1069 macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild
- 1070 cognitive impairment or Parkinson's disease. *Journal of Neuroimmunology* **283**, 50–57

1071 (2015).

- 1072 99. Yang, H.-S. *et al.* Plasma IL-12/IFN-γ axis predicts cognitive trajectories in cognitively
  1073 unimpaired older adults. *Alzheimers Dement* **18**, 645–653 (2022).
- 1074 100. Sutinen, E. M., Pirttilä, T., Anderson, G., Salminen, A. & Ojala, J. O. Pro-
- 1075 inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β
- 1076 production in human neuron-like cells. *Journal of Neuroinflammation* **9**, 199 (2012).
- 1077 101. Brosseron, F. et al. Soluble TAM receptors sAXL and sTyro3 predict structural and
- 1078 functional protection in Alzheimer's disease. *Neuron* **110**, 1009-1022.e4 (2022).
- 1079 102. Shin, J. J. *et al.* MIF is a common genetic determinant of COVID-19 symptomatic
  1080 infection and severity. *QJM* **116**, 205–212 (2023).
- 1081 103. Nasiri, E. *et al.* Key role of MIF-related neuroinflammation in neurodegeneration and
- 1082 cognitive impairment in Alzheimer's disease. *Mol Med* **26**, 34 (2020).

1083

# Supplementary Information

1089	Tables not shown can be	found in the accomp	panying Excel	spreadsheet.

#### 1092

CLASS	COVARIATE	UKB DATA- FIELD ID(S)	CASE/CONTROL COMPARISON	BASIC MODEL	AD RISK FACTORS MODELS
DEMOGRAPHICS	Age	34,52,53	Х	Х	X
	Sex	31	Х	Х	Х
	Height (cm)	50	Х		
	Weight (kg)	21002	Х		Х
	Ethnicity (White)	21000	Х		Х
ASSESSMENT INFORMATION	Date of assessment/ interval	53	X	Х	X
GENETICS	APOE status	Genotyping	X		X
HEALIH MEASURES	Body Mass Index	21001	X		X
	Rlood Pressure	40,49	A V		A V
	(Diastolic, Systolic) Hand arip strenath	46.47	X		Λ
	Chest Wheeze	2316	X		
	Est. Glomerular	OLINK: P.CST3	Х		Х
	Filtration Rate	2170	V		V
	General Health	2178	X		X
LIFE STATUS	Alcohol Intake Freq	1558	X		X
	Smoking status	1239	X		X
	Years of education	845	X		Χ
	Deprivation	26410	X		
	Income	/38	X		W.
	Household Size	709	X		Х
	Employment status	6142	X		
	Key Worker Status	28063	X		
	Activity levels (min/day) Isolation (social visits)	894,914	X		X
COMORRIDITIES	Type II Dichetes	26206	X		X Y
COMORDIDITIES	Heart Condition	20200	X		Y
	Ohesity	21001	X		X Y
	Hypertension	20002	X		X X
	Depression	20002	X		X V
	Irritable Rowel	20002	X		X
	Syndrome	20002	~		<u> </u>
	COPD	20002	Х		Х
	Emphysema	20002	Х		Х
	Renal conditions	20002	Х		Х
MEDICATION	Blood pressure medication	6153	X		
	Diabatas medication	6152	A V		
	COULD up again at in a	Ucolth Dorrad	л V		
COCNITION	Covid vaccination	Gegnitive test	A V		v
LUGNITION	Ability score	fields	Λ		Λ
NEUROIMAGING	AD imaging phenotype	FreeSurfer IDPs	X		Х

1093

Supplementary table 1. UK Biobank Covariates used in analyses. BMI: Body Mass Index; AD: Alzheimer's
 Disease, PRS: polygenic risk score. COPD - Chronic obstructive pulmonary disease

1096				
1097 1098 1099 1100	Supplementary table 2 Parameter fits for linear model session. Table shows model fits and p-values associa (male=+1), the time interval between sessions (days), standardised. NfL – neurofilament light; GFAP (**) ind	predicting pro ted with case and pre-pand licates significa	teomic levels in / control status ( emic protein leve ant, FDR correct	pandemic assessment case=+1), age, sex el. Beta estimates have been ed by column, alpha=0.05.
1101 1102 1103	Supplementary table 3 Parameter fits for linear model session with an extended set of confound variables. E light; GFAP (**) indicates significant, FDR corrected b	l predicting pro Beta estimates y column, alph	teomic levels in have been stand a=0.05.	pandemic assessment dardised. NfL – neurofilament
1104 1105 1106 1107	Supplementary table 4 Parameter fits for linear model session with additional terms modelling age-related vuestimates have been standardised. NfL – neurofilame. column, alpha=0.05.	predicting pro ulnerability and nt light; GFAP	teomic levels in I its interaction v (**) indicates sig	pandemic assessment vith case/control status. Beta gnificant, FDR corrected by
1108 1109 1110 1111	Supplementary table 5 Parameter fits for linear model predicting proteomic levels in pandemic assessment session with additional terms modelling age-related vulnerability and its interaction with case/control status, and an extended set of confound variables. Beta estimates have been standardised. NfL – neurofilament light; GFAP (**) indicates significant, FDR corrected by column, alpha=0.05.			
1112 1113 1114	Supplementary table 6 Associations of protein biomarkers with UK Biobank variables at pre-pandemic assessment visit. Associations were determined from linear models including age and sex covariates. (*) p<0.05 uncorrected (**) p<0.05 FDR correction (alpha = 0.05).			
1115	Supplementary table 7 Baseline protein level statistics	s for cases and	l controls. P-val	ues reflect paired t-tests.
1116 1117 1118 1119	Supplementary table 8 Parameter fits for linear model predicting proteomic levels in pandemic assessment session with additional terms modelling covariates APOE variant status, smoking status, Hip/Waist ratio and Diabetes. Beta estimates have been standardised. NfL – neurofilament light; GFAP (**) indicates significant, FDR corrected by column, alpha=0.05.			
1120 1121 1122 1123	Supplementary table 9 Associations of UK Biobank variables (measured at pre-pandemic assessment) with the change in protein biomarkers across assessments (post-pandemic – pre-pandemic). Associations were determined from linear models of protein level change including terms for age, sex, and interval between assessments. (*) p<0.05 uncorrected (**) p<0.05 FDR correction (alpha = 0.05).			
1124 1125 1126 1127	Supplementary table 10 Parameter fits for linear model predicting proteomic levels in pandemic assessment session with additional terms modelling covariates APOE variant status, smoking status, Hip/Waist ratio and Diabetes. Beta estimates have been standardised. NfL – neurofilament light; GFAP (**) indicates significant, FDR corrected by column, alpha=0.05.			
1128 1129 1130 1131	Supplementary table 11 Parameter fits for linear model predicting proteomic levels in pandemic assessment session with additional term modelling potential confound Glomerular Filtration Rate (GFR). GFR was available in around half of participants. Beta estimates have been standardised. NfL – neurofilament light; GFAP (**) indicates significant, FDR corrected by column, alpha=0.05.			
1132 1133 1134 1135	Supplementary table 12 Parameter fits for interaction term with case-control status (case=+1) and associations between UK Biobank variables at baseline with protein biomarker change. These terms identify UK Biobank variables associated with the protein biomarkers in SARS-CoV-2 exposure specific manner. (*) p<0.05 uncorrected (**) p<0.05 FDR correction (alpha = 0.05).			
1136 1137 1138	Supplementary table 13 AD protein level change mod neuroimaging phenotype at baseline. Associations we covariates. (*) p<0.05 uncorrected (**) p<0.05 FDR co	lel fits for mode ere determined prrection (alpha	els including tern d from linear mod a = 0.05).	ns modelling AD dels including age and sex
1139 1140				
;			AD	
	I UMOUR NECROSIS FACTOR ALPHA $(TNF-\alpha)$	X*'	X <sup>04</sup>	
	TNF SUPERFAMILY MEMBER 10 (TRAIL)	X <sup>47</sup>	X <sup>42</sup>	
	INTERLEUKIN(IL)-1α	X <sup>97</sup>	X <sup>98</sup>	
	IL-6	X <sup>47,71</sup>	X <sup>98</sup>	
	IL-12		X <sup>99</sup>	

IL-18	X <sup>97</sup>	X <sup>100</sup>
IFN-B	X <sup>71</sup>	X <sup>42,98</sup>
INTERFERON GAMMA (IFNG)	X <sup>71</sup>	X <sup>100</sup>
COMPLEMENT C1QA		X <sup>101</sup>
COMPLEMENT C4BPB		X <sup>101</sup>
MACROPHAGE INHIBITORY FACTOR (MIF)	X <sup>102</sup>	X <sup>101,103</sup>
CHITINASE-3 LIKE-PROTEIN-1 (CHI3L1)		X <sup>42</sup>
- YKL-40	74	
PENTRAXIN 3 (PTX3)	X′1	
CALCITONIN (CALCA)	X <sup>47</sup>	

1141

Supplementary table 14 Inflammatory proteins available from Olink panel identified as associated with COVID and/or Alzheimer's Disease. X indicates reports of an association with the disease.

1144 Supplementary table 15 Baseline Case-Control differences in Olink Inflammatory Proteins. P-values reflect paired 1145 t-tests.

1146Supplementary table 16 Associations of Olink Inflammatory Protein levels (measured at baseline) with the<br/>change in AD protein biomarkers across assessments (across cases and controls). Associations were<br/>determined from linear models including terms for age, sex, and interval between assessments. (\*) p<0.051149uncorrected (\*\*) p<0.05 FDR correction (alpha = 0.05).

Supplementary table 17 Associations of an interaction term between Case/Control status and Olink Inflammatory Protein levels (measured at baseline) with protein biomarker change. These identify Olink Inflammatory Proteins associated with the AD protein biomarkers in a SARS-CoV-2 exposure specific manner. Associations were determined from linear models including terms for age, sex, and interval between assessments. (\*) p<0.05</li>
uncorrected (\*\*) p<0.05 FDR correction (alpha = 0.05).</li>

1155Supplementary table 18 Parameter fits for linear model predicting Olink Inflammatory Protein levels in pandemic1156assessment session. Beta estimates have been standardised. (\*\*) indicates significant, FDR corrected by1157column, alpha=0.05.

1158Supplementary table 19 SARS-CoV-2 related increases in Olink ProteinScore disease risk scores. Plots show1159SARS-CoV-2 effect weighting parameter in model of change of scores between assessment visits. Due to the1160ProteinScore disease risk training data, results are from participants <73 years. (\*) reflects FDR corrected</td>1161significance, alpha=0.05.

Supplementary table 20 Correlations between Simoa Ultrasensitive neurology assays. Diagonal reflects correlations of protein levels between pre-pandemic and pandemic assessment visits.

1164